CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

FDA Grants Priority Review to AZN's Filing for Rare Bone Disease Drug

RegulatoryPositive
AI Analysis

Summary

FDA has granted Priority Review status to AstraZeneca's filing for a rare bone disease drug, expediting the review process.

Outcome Details

Priority Review granted

Importance:6/10
Sentiment:
0.70
FDAPriority Reviewrare diseaseregulatory
Related Companies

Read the original article

Published by yahoo_finance on September 18, 2026 5:00 PM

Read Original